The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathologic and allele-specific analysis of germline ATM alterations in a pan-cancer cohort.
 
Matteo Repetto
No Relationships to Disclose
 
Daniel Muldoon
No Relationships to Disclose
 
Pier Selenica
No Relationships to Disclose
 
Kanika Arora
No Relationships to Disclose
 
Ying Liu
Consulting or Advisory Role - Myriad Genetics
Research Funding - Artios (Inst); AstraZeneca (Inst); Repare Therapeutics (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Myriad Genetics
 
Marie Carlo
Honoraria - OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Other Relationship - Kidney Cancer Association; Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Lauren Banaszak
No Relationships to Disclose
 
Alicia Latham
No Relationships to Disclose
 
Chaitanya Bandlamudi
No Relationships to Disclose
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Mark Robson
Consulting or Advisory Role - OptumHealth
Research Funding - Artios (Inst); AstraZeneca (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - Clinical Care Options; Clinical Education Alliance; MJH Healthcare Holdings, LLC; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; Foundation Medicine; GlaxoSmithKline; Merck; Pfizer; Tempus; Zenith Pharmaceuticals
 
Benoit Rousseau
No Relationships to Disclose
 
Diana Mandelker
Consulting or Advisory Role - AstraZeneca
 
Alexander Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Britta Weigelt
Employment - AstraZeneca (I)
Stock and Other Ownership Interests - Repare Therapeutics (I)
Consulting or Advisory Role - Bain Capital Life Sciences (I); PAIGE (I); Repare Therapeutics (I); SAGA Diagnostics (I); Volition RX (I)
Research Funding - Repare Therapeutics (Inst); SAGA Diagnostics (Inst)
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
Michael Berger
Honoraria - SOPHiA Genetics
Consulting or Advisory Role - AstraZeneca; PAIGE.AI
Research Funding - Boundless Bio
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Yonina Murciano-Goroff
Employment - Memorial Sloan Kettering Cancer Center (MSK has institutional financial interests relative to Elucida Oncology); Memorial Sloan-Kettering Cancer Center
Honoraria - Amgen; Virology Education
Consulting or Advisory Role - Abbvie; Revolution Medicines
Research Funding - Abbvie (Inst); Andrew Sabin Family Foundation; Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation; Druckenmiller Center for Lung Cancer Research; Elucida Oncology (Inst); Endeavor BioMedicines (Inst); Hengrui Pharmaceutical (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo/Lilly (Inst); Luzsana Biotechnology (Inst); Mirati Therapeutics (Inst); National Cancer Institute; National Cancer Institute; National Institutes of Health (NIH)/National Cancer Institute (NCI); Squeri Grant for Drug Development; Taiho Oncology (Inst); The Society of Memorial Sloan Kettering
Patents, Royalties, Other Intellectual Property - Rutgers University Press; Wolters Kluwer
Travel, Accommodations, Expenses - AstraZeneca; Loxo Oncology/ Eli Lilly
Other Relationship - Endeavor Biomedicines
 
Zsofia Stadler
Consulting or Advisory Role - Adverum (I); Genentech/Roche (I); Neurogene (I); Novartis (I); Optos (I); Outlook Therapeutics (I); Regeneron (I)
Patents, Royalties, Other Intellectual Property - Intellectual property rights (SOPHiA Genetics) (Inst)
Other Relationship - JCO Precision Oncology, Associate Editor; UpToDate, Section Editor
 
Mohammad Ali Abbass
No Relationships to Disclose